NASDAQ:OM

Outset Medical Reports Unaudited Fourth Quarter and 2023 Revenue, Provides 2024 Revenue and Non-GAAP Gross Margin Guidance

Retrieved on: 
Monday, January 8, 2024
Health Technology, Health, Other Health, Medical Devices, Medicine, Growth, Investment, Patient, Dialysis, ICU, Video game

Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported unaudited revenue for the fourth quarter and fiscal year ended December 31, 2023, and provided 2024 financial guidance.

Key Points: 
  • Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported unaudited revenue for the fourth quarter and fiscal year ended December 31, 2023, and provided 2024 financial guidance.
  • Unaudited Fourth Quarter and Year End Results, and Recent Highlights
    Revenue in the fourth quarter totaled $30.5 million, bringing revenue for 2023 to $130 million, a 13% increase compared to $115 million in 2022.
  • Consumable revenue grew nearly 50% year-over-year driven by strong utilization of Tablo consoles in the acute and home settings, and contributing to recurring revenue of more than 50% of total revenue in 2023.
  • Non-GAAP gross margin is expected to expand to the low-30% range for the full year 2024 and exit the year in the mid-30% range for the fourth quarter of 2024.

Outset Medical to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, January 3, 2024
FDA, Health Technology, Health, Medical Devices, Medicine, Dialysis

Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will present at the 42nd annual J.P. Morgan Healthcare conference on Monday, January 8, 2024, at 5:15 p.m. Pacific time.

Key Points: 
  • Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will present at the 42nd annual J.P. Morgan Healthcare conference on Monday, January 8, 2024, at 5:15 p.m. Pacific time.

Outset Medical (OM) Investigated for Possible Securities Law Violations: Hagens Berman, National Trial Attorneys, Encourages Investors with Losses to Contact the Firm’s Attorneys

Retrieved on: 
Thursday, November 16, 2023
SAN, Person, Letter, Dialysis, FDA, Hagens Berman, Life insurance, Medical device, Pharmaceutical industry, Outset Contemporary Art Fund

SAN FRANCISCO, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Outset Medical, Inc. (NASDAQ: OM) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Outset Medical, Inc. (NASDAQ: OM) investors who suffered substantial losses to submit your losses now .
  • In late July 2022, Outset disclosed the FDA cleared the 510(k) application of Tablo for patient use in the home.
  • More recently, on Oct. 12, 2023, Outset Medical reported disappointing preliminary Q3 2023 revenues and slashed its FY 2023 revenue guidance.
  • “We’re focused on investors’ losses and investigating whether Outset may have misled investors about Tablo’s near-term prospects,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Outset Medical, Inc. - OM

Retrieved on: 
Monday, November 13, 2023
Chronic kidney disease, LLP, Letter, FDA, Marketing, Hemofiltration, Health, Diabetes, News, Novo Nordisk, Pomerantz, CRRT

NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Outset Medical, Inc. (“Outset” or the “Company”) (NASDAQ: OM).

Key Points: 
  • NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Outset Medical, Inc. (“Outset” or the “Company”) (NASDAQ: OM).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Outset and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Outset Medical to Present at BofA Home Care Conference

Retrieved on: 
Wednesday, November 29, 2023
Biotechnology, Health Technology, Health, Medical Devices, Kidney disease, Bank of America, Conference, Medicine, MD, Dialysis, Medical device

Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will participate in a virtual panel discussion at the BofA Securities Home Care Conference on Monday, December 4, 2023, at 12:00pm PT / 3:00pm ET.

Key Points: 
  • Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will participate in a virtual panel discussion at the BofA Securities Home Care Conference on Monday, December 4, 2023, at 12:00pm PT / 3:00pm ET.
  • The panel discussion will include Leslie Trigg, Outset’s Chair and Chief Executive Officer, Michael Aragon, MD, Outset’s Chief Medical Officer, a home healthcare provider, and a patient currently dialyzing at home with the Tablo® Hemodialysis System.
  • The discussion will focus on home hemodialysis and managing end-stage renal disease.

Outset Medical to Present at Upcoming Investor Conferences

Retrieved on: 
Thursday, November 9, 2023
Biotechnology, Health Technology, Health, Medical Devices, Conference, Medicine, Dialysis, Pharmaceutical industry

Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will participate in fireside chats at two upcoming investor conferences.

Key Points: 
  • Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will participate in fireside chats at two upcoming investor conferences.
  • Outset will participate in the Stifel 2023 Healthcare Conference on Tuesday, November 14, 2023, and the Jefferies London Healthcare Conference on Thursday, November 16, 2023.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Outset Medical (OM) Shareholders with Losses to Contact its Attorneys, Firm Investigating Possible Securities Law Violations

Retrieved on: 
Tuesday, November 7, 2023
Person, FDA, OM, Letter, Dialysis, Hagens Berman, Medical device, Pharmaceutical industry, Life insurance, Outset Contemporary Art Fund

As a result, Outset suspended 2022 and long-term financial guidance.

Key Points: 
  • As a result, Outset suspended 2022 and long-term financial guidance.
  • In late July 2022, Outset disclosed the FDA cleared the 510(k) application of Tablo for patient use in the home.
  • More recently, on Oct. 12, 2023, Outset Medical reported disappointing preliminary Q3 2023 revenues and slashed its FY 2023 revenue guidance.
  • “We’re focused on investors’ losses and investigating whether Outset may have misled investors about Tablo’s near-term prospects,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

Outset Medical Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 7, 2023
Biotechnology, Health Technology, Health, Medical Devices, S&M, Medicine, G&A, GAAP, Research, R, Bank statement, Dialysis, Growth, Appendix, Marketing, Webcast, Investment, Patient, Video game, Fine chemical, Bank

Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the third quarter ended September 30, 2023.
  • Total gross profit was $7.2 million, compared to $4.3 million for the third quarter of 2022.
  • Product gross profit was $6.7 million, compared to $2.1 million of product gross profit in the third quarter of 2022.
  • ET to discuss its third quarter 2023 financial results.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Outset Medical, Inc. - OM

Retrieved on: 
Sunday, November 5, 2023
FDA, Novo Nordisk, News, Diabetes, CRRT, Hemofiltration, Chronic kidney disease, Pomerantz, LLP, Marketing, Health, Letter, Pharmaceutical industry

NEW YORK, Nov. 05, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Outset Medical, Inc. (“Outset” or the “Company”) (NASDAQ: OM).

Key Points: 
  • NEW YORK, Nov. 05, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Outset Medical, Inc. (“Outset” or the “Company”) (NASDAQ: OM).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Outset and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Outset Medical (OM) Investigated for Possible Securities Law Violations: Hagens Berman, National Trial Attorneys, Encourages Investors with Losses to Contact the Firm

Retrieved on: 
Tuesday, October 31, 2023
Person, FDA, OM, Letter, Dialysis, Hagens Berman, Medical device, Pharmaceutical industry, Life insurance, Outset Contemporary Art Fund

As a result, Outset suspended 2022 and long-term financial guidance.

Key Points: 
  • As a result, Outset suspended 2022 and long-term financial guidance.
  • In late July 2022, Outset disclosed the FDA cleared the 510(k) application of Tablo for patient use in the home.
  • More recently, on Oct. 12, 2023, Outset Medical reported disappointing preliminary Q3 2023 revenues and slashed its FY 2023 revenue guidance.
  • “We’re focused on investors’ losses and investigating whether Outset may have misled investors about Tablo’s near-term prospects,” said Reed Kathrein, the Hagens Berman partner leading the investigation.